Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2021-08-13 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '차바이오텍' (Chabiotech) covering the period from January 1, 2021, to June 30, 2021. It contains detailed financial information, business operations, management discussions, and corporate governance details, which are characteristic of an interim financial report. It is not a mere announcement or certification, as it provides substantive financial data and operational details. H1 2021
2021-08-13 Korean
[기재정정]반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Cha Biotech, which is a comprehensive financial report covering the first half of the fiscal year (2021.01.01-2021.06.30). It contains detailed financial statements, management discussion, and operational data. It is not an announcement of a report (RPA) or a simple certification, but the report itself. Therefore, it is classified as an Interim/Quarterly Report. H1 2021
2021-08-13 Korean
주식등의대량보유상황보고서(일반)
Regulatory Filings Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status, changes in ownership, and special relationships of the reporting person (Cha Kwang-yul) and related parties regarding the company 'Cha Biotech'. This type of filing is a mandatory regulatory disclosure for significant shareholders and does not fit into other categories like financial reports or press releases. Therefore, it is classified as a Regulatory Filing (RNS).
2021-07-23 Korean
전환청구권행사(제6회차)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Cha Biotech regarding the exercise of conversion rights (전환청구권행사) for convertible bonds (6th series). It details the number of shares issued, the conversion price, and the remaining balance of the convertible bonds. This type of filing relates to changes in capital structure due to the conversion of debt into equity, which falls under the 'Share Issue/Capital Change' category.
2021-07-23 Korean
신주인수권행사(제7회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Cha Biotech regarding the exercise of stock warrants (신주인수권행사). It details the number of shares issued, the exercise price, and the impact on total outstanding shares. This falls under the category of capital changes resulting from the exercise of financial instruments, which is best classified as Share Issue/Capital Change (SHA).
2021-07-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the share ownership, special relationships, and changes in collateralized stock agreements for Cha Kwang-yul and related parties regarding Cha Biotech. This type of filing is a standard regulatory disclosure for significant shareholding changes, which falls under the 'Major Shareholding Notification' category.
2021-07-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.